Vitrolife AB (OSTO:VITR) Beneish M-Score: -4.99 (As of Jun. 27, 2026)


OSTO:VITR Vitrolife AB OSTO:VITR
78 GF Score
Price kr89.65
GF Value kr162.15
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Vitrolife AB Beneish M-Score?

Vitrolife AB OSTO:VITR +0.11% 78 Beneish M-Score is -4.99 as of Jun. 27, 2026. GuruFocus rates OSTO:VITR with a GF Score™ of 78/100 and a GF Value™ of kr162.15 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 766 Medical Devices & Instruments companies, Vitrolife AB ranks better than 96.48% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -4.99 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Vitrolife AB's Beneish M-Score or its related term are showing as below:

OSTO:VITR' s Beneish M-Score Range Over the Past 10 Years
Min: -4.99   Med: -2.46   Max: 0.56
Current: -4.99

During the past 13 years, the highest Beneish M-Score of Vitrolife AB was 0.56. The lowest was -4.99. And the median was -2.46.


Vitrolife AB Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Vitrolife AB's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitrolife AB Beneish M-Score Chart

Vitrolife AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.31 -1.95 -3.82 -2.31 -4.95

Vitrolife AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.49 -2.51 -2.59 -4.95 -4.99

OSTO:VITR vs ABT, SYK, MDT: Beneish M-Score Comparison

For the Medical Devices subindustry, Vitrolife AB's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vitrolife AB Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Vitrolife AB's Beneish M-Score falls into.


OSTO:VITR
78GF Score
Vitrolife AB OSTO:VITR
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vitrolife AB Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Vitrolife AB for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1398+0.528 * 1.0112+0.404 * 0.9036+0.892 * 0.9432+0.115 * 0.7031
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1486+4.679 * -0.511386-0.327 * 1.3091
=-4.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was kr802 Mil.
Revenue was 807 + 891 + 835 + 871 = kr3,404 Mil.
Gross Profit was 483 + 517 + 492 + 505 = kr1,997 Mil.
Total Current Assets was kr2,179 Mil.
Total Assets was kr11,242 Mil.
Property, Plant and Equipment(Net PPE) was kr549 Mil.
Depreciation, Depletion and Amortization(DDA) was kr123 Mil.
Selling, General, & Admin. Expense(SGA) was kr1,209 Mil.
Total Current Liabilities was kr592 Mil.
Long-Term Debt & Capital Lease Obligation was kr1,536 Mil.
Net Income was 101 + -5314 + 102 + 100 = kr-5,011 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = kr0 Mil.
Cash Flow from Operations was 172 + 160 + 255 + 151 = kr738 Mil.
Total Receivables was kr746 Mil.
Revenue was 842 + 959 + 867 + 941 = kr3,609 Mil.
Gross Profit was 483 + 586 + 508 + 564 = kr2,141 Mil.
Total Current Assets was kr2,279 Mil.
Total Assets was kr16,632 Mil.
Property, Plant and Equipment(Net PPE) was kr413 Mil.
Depreciation, Depletion and Amortization(DDA) was kr61 Mil.
Selling, General, & Admin. Expense(SGA) was kr1,116 Mil.
Total Current Liabilities was kr605 Mil.
Long-Term Debt & Capital Lease Obligation was kr1,800 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(802 / 3404) / (746 / 3609)
=0.235605 / 0.206705
=1.1398

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2141 / 3609) / (1997 / 3404)
=0.593239 / 0.586663
=1.0112

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2179 + 549) / 11242) / (1 - (2279 + 413) / 16632)
=0.757339 / 0.838143
=0.9036

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=3404 / 3609
=0.9432

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(61 / (61 + 413)) / (123 / (123 + 549))
=0.128692 / 0.183036
=0.7031

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1209 / 3404) / (1116 / 3609)
=0.35517 / 0.309227
=1.1486

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1536 + 592) / 11242) / ((1800 + 605) / 16632)
=0.18929 / 0.144601
=1.3091

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-5011 - 0 - 738) / 11242
=-0.511386

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Vitrolife AB has a M-score of -4.99 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -4.99 mean?
Vitrolife AB (OSTO:VITR) has a Beneish M-Score of -4.99 as of Jun. 27, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Vitrolife AB and its competitors. According to the industry distribution chart, Vitrolife AB ranks #27 out of 766 companies in the Medical Devices & Instruments industry, placing it in the top 3.5%.
Is Vitrolife AB's Beneish M-Score too high?
Vitrolife AB's current Beneish M-Score is -4.99. Based on the distribution chart, Vitrolife AB ranks #27 out of 766 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Vitrolife AB has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's Beneish M-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vitrolife AB ranks #27 out of 766 companies for Beneish M-Score. This places Vitrolife AB in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Vitrolife AB and its competitors. Vitrolife AB's current Beneish M-Score is -4.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Based on GuruFocus' analysis, Vitrolife AB (OSTO:VITR) is currently considered Possible Value Trap. The stock's GF Value™ is kr162.15, compared to a current price of kr89.65 — trading 44.7% below its estimated fair value. The current Beneish M-Score is -4.99. Vitrolife AB's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Vitrolife AB (OSTO:VITR), the current Beneish M-Score is -4.99 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vitrolife AB (OSTO:VITR) Overvalued in 2026?

Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued. The current stock price of kr89.65 is trading 44.7% below its estimated GF Value™ of kr162.15. GuruFocus considers Vitrolife AB to be Possible Value Trap.

Key valuation signals for OSTO:VITR:

  • Beneish M-Score: -4.99
  • GF Value™: kr162.15 vs. price of kr89.65 (44.7% below fair value)
  • GF Score™: 78/100 with 6 warning signs

No single metric tells the full story. See the OSTO:VITR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vitrolife AB Business Description

Address Box 9080, Gothenburg, SWE, 400 92
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
78GF Score

Get the complete analysis for OSTO:VITR

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr89.65
Price
kr162.15
GF Value